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Enhanced Inflammasome Activity in
Systemic Lupus Erythematosus Is Mediated via
Type I Interferon–Induced Up-Regulation of
Interferon Regulatory Factor 1
Jianhua Liu, Celine C. Berthier, and J. Michelle Kahlenberg
Objective. The inflammasome complex is a driver
of organ damage in patients with systemic lupus erythe-
matosus (SLE). Although type I interferons (IFNs)
are well established as mediators of SLE pathogenesis,
their role in inflammasome activation in SLE has not
been assessed. The aim of this study was to examine
type I IFNs as regulators of the inflammasome.
Methods. SLE patients fulfilled ‡4 American
College of Rheumatology criteria and were recruited
from the University of Michigan Lupus Cohort.
Primary monocytes were isolated from SLE patients or
healthy controls by negative selection, treated with
inflammasome activators in the presence or absence of
IFNa, and IL-1b secretion was measured by enzyme-
linked immunosorbent assay. Expression levels of IFN
and inflammasome-related molecules were assessed by
real-time polymerase chain reaction and Western blot-
ting. IFN regulatory factor 1 (IRF-1) expression was
specifically down-regulated by small interfering RNA
(siRNA) transfection and a chemical inhibitor.
Results. Monocytes from patients with SLE
exhibited increased expression and enhanced activation
of the inflammasome by ATP when compared with
control monocytes. Expression of inflammasome and
IFN-regulated genes was significantly correlated in
monocytes from SLE patients but not in control mono-
cytes. Inflammasome activity was increased after pro-
longed exposure to IFNa. Reduction of IRF-1 expression via
siRNA blocked caspase 1 up-regulation after treatment with
IFNa. Importantly, hyperactivity of the inflammasome in
the monocytes of SLE patients was significantly reduced
after knockdown or inhibition of IRF-1.
Conclusion. Prolonged type I IFN exposure, as
seen in SLE patients, primes monocytes for robust inflam-
masome activation in an IRF-1–dependent manner. IRF-1
inhibition may serve as a novel target for treatment of
SLE-associated inflammation and organ damage.
Systemic lupus erythematosus (SLE) is a chronic
autoimmune disease characterized by formation of
autoantibodies, deposition of immune complexes, and
pleotropic end-organ damage. Dysregulation of both
the innate and adaptive immune responses is central to
the development of SLE, and recent evidence from human
and murine studies identifies the innate signaling complex
termed the inflammasome as being dysregulated in SLE
and a central contributor to the development of lupus
nephritis and the associated organ damage (1–10).
Inflammasomes are multiprotein complexes that
use a central scaffold and adaptor molecules to recruit
and activate caspase 1. Active caspase 1 then cleaves
the proinflammatory cytokines interleukin-1b (IL-1b)
and IL-18 to their active forms. The best-characterized
inflammasome is one that contains the nucleotide-
binding oligomerization domain NLRP3, the adaptor
molecule ASC protein that contains a caspase recruit-
ment domain, and caspase 1. This inflammasome com-
plex is hyperactivated in the macrophages of lupus
patients (2), is activated by lupus-specific autoantibodies
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(1,6,7), and contributes to the development of nephritis
(11,12).
Despite the plethora of research showing the
importance of the inflammasome in SLE, the mecha-
nisms that regulate inflammasome activation in this dis-
ease have not been well characterized. Experimental
evidence collected in the past decade has identified type
I interferons (IFNs), particularly IFNa, as being impor-
tant contributors to the pathogenesis of SLE in humans
and murine models (13–18). Many patients with SLE
have elevated levels of IFN-induced gene expression, or
the “IFN signature,” which correlate with the presence
of autoantibodies, nephritis, and disease activity (18).
The effects of type I IFNs on inflammasome activity are
unclear. Previous studies have identified type I IFN sig-
naling as a negative regulator of inflammasome gene
expression and activity in peripheral blood mononuclear
cells (PBMCs) and bone marrow–derived macrophages
(19,20). However, other studies have identified correla-
tions between increased IFN-induced gene expression
and activation of the inflammasome in SLE (4,21).
Monocytes are sentinels of the IFN signature in
autoimmune diseases (22) and are also an important
source of inflammasome activation. Thus, in this study
we chose to clarify the effects of IFNa on inflamma-
some function in both control monocytes and those
from lupus patients in order to better understand how
an environment with persistently activated type I IFNs,
as seen in SLE patients, changes inflammasome activity.
We observed increased inflammasome activity in mono-
cytes from SLE patients and identified the chronicity of
IFNa exposure as a dichotomous regulator of this activ-
ity. Importantly, we demonstrated that IFNa-induced
up-regulation of IFN regulatory factor 1 (IRF-1) is
required for up-regulation of caspase 1 and enhanced
IL-1b production by monocytes from patients with
SLE. Our results identify an important intersection
between type I IFNs and the inflammasome and may
suggest an additional mechanism by which blockade of
type I IFN signaling may result in improvement in SLE
activity (23).
PATIENTS AND METHODS
Reagents and antibodies. Ficoll-Paque Plus and fetal
bovine serum (FBS) were obtained from GE Healthcare. Lipo-
polysaccharide (LPS) was purchased from Sigma-Aldrich,
RPMI 1640 was purchased from Lonza, recombinant IFNa was
obtained from Schering, and 4,5,6,7-tetrabromobenzotriazole
(TBB) was purchased from Tocris. Anti-human IRF-1 (D5E4),
caspase 1 (D7F10), pSTAT-1 (Tyr701) (D4A7), pSTAT-2
(Tyr690) (D3P2P), STAT-1 (D1K9Y), STAT-2, and b-actin
were purchased from Cell Signaling Technology. Horseradish
peroxidase (HRP)–conjugated goat anti-rabbit IgG was obtained
from Abcam.
Study subjects. All prospectively recruited patients
and control subjects provided written, informed consent and
were treated according to the Declaration of Helsinki. The
study protocol was approved by the Institutional Review
Board of the University of Michigan Medical School. The
patients with SLE fulfilled $4 American College of Rheuma-
tology criteria (24) and were recruited from the University of
Michigan Lupus Cohort. We recruited 23 patients in whom
SLE was diagnosed and treated at the University of Michigan
Hospital clinic and 23 sex-, age-, and race-matched healthy
control subjects for studies that compared monocytes from
patients with SLE with control monocytes. An additional 25
control subjects were recruited for studies on control cells
alone. Table 1 shows the characteristics of the patients. For
the microarray study, 90 cases of discoid lupus erythematosus
(DLE) and subacute cutaneous lupus erythematosus (SCLE)
were identified via a Systematized Nomenclature of Medicine
search of the University of Michigan Pathology Database using
the search terms “lupus” and “cutaneous lupus.” Patients who
met both clinical and histologic criteria for DLE or SCLE
were included in the study.
Human peripheral monocyte preparation. Heparin-
ized blood (50 ml) was obtained from patients with SLE
and control subjects. The buffy coat was obtained after den-
sity-gradient centrifugation on 15 ml Ficoll-Paque Plus (5:3
blood:Ficoll ratio). Red blood cells were removed via hypo-
tonic lysis. CD141CD16– monocytes were isolated using nega-
tive selection using an EasySep Human Monocyte Enrichment
Kit (StemCell Technologies). Monocyte population purity was
assessed by flow cytometry and judged to be 87% after nega-
tive selection.
Monocyte culture and treatment. Monocytes from
control subjects and patients with SLE were plated onto 48-
well or 96-well tissue culture plates at a density of 0.5 3 106
cells/well in 0.5 ml RPMI 1640 plus 10% FBS or 0.2 3 106
cells/well in 0.2 ml RPMI 1640 plus 10% FBS, respectively.
Monocytes were cultured overnight in the presence or absence
Table 1. Characteristics of the 23 patients with SLE*
Age, mean6 SEM years 44.96 2.3
Sex
Female 91
Male 9
Medication
Oral prednisone #10 mg/day 35
Oral prednisone .10 mg/day 0
Mycophenolate mofetil 30
Belimumab 9
Antimalarial agent 87
Methotrexate 0
Antibody status
ANA positive, ever 78
Anti-DNA positive, at time of sampling 52
Titer, mean (range) IU/ml 63.6 (0–337)
SLEDAI score at time of sampling, mean (range) 2.7 (0–9)
* Among the 48 control subjects, the mean6 SEM age was 41.56 1.5
years, 90% were female, and 10% were male. Except where indicated
otherwise, values are the percent. ANA5 antinuclear antibody;
SLEDAI5 Systemic Lupus Erythematosus Disease Activity Index.
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of 1,000 units/ml human IFNa. In some cases, 50 mM TBB was
added 1 hour prior to IFN treatment. The next morning, the
cells were stimulated with or without 100 ng/ml LPS or vehicle
for 4 hours. This was followed by treatment with 5 mM ATP to
stimulate inflammasome activation. In some experiments, IFNa
was also used concurrently with LPS. To assess the effects of
serum from SLE patients and serum from control subjects on
inflammasome activity, monocytes were cultured in 50% serum
overnight in the presence or absence of 50 mM TBB prior to
inflammasome activation with LPS and ATP.
Enzyme-linked immunosorbent assay (ELISA) and
Western blotting. The supernatants from cultured monocytes
were assayed for IL-1b using IL-1b human ELISA Ready-
SET-Go kits (eBioscience) according to the instructions of the
manufacturer.
For Western blot analysis, monocyte cultures were
directly lysed in 23 protein sample buffer after supernatant
removal. Protein from each sample (0.8 3 105 cells) was sepa-
rated on 10% or 12% acrylamide gel and then transferred to
Amersham Protran 0.2 mm NC nitrocellulose membranes (GE
Healthcare). The membranes were blocked with 5% nonfat dry
milk and incubated overnight at 48C with primary antibodies
(1:1,000 dilution) followed by HRP-conjugated anti-rabbit IgG.
Protein expression bands were detected by chemiluminescence
using WesternBright Quantum Western blot detection reagent
(Advansta), and the protein bands were imaged using an
Omega Lum C System (Gel Company). Expression quantifica-
tion was completed using ImageJ software.
RNA isolation and real-time quantitative polymerase
chain reaction (qPCR). Total RNA was isolated from human
monocytes using a Direct-zol RNA MiniPrep kit (Zymo
Research Corporation) according to the instructions of the manu-
facturer. One microgram of total RNA was transcribed into com-
plementary DNA (cDNA) using Moloney murine leukemia virus
reverse transcriptase and oligo(dT) primer (Invitrogen). Real-
time qPCR was performed in triplicate using SYBR Green PCR
Master Mix (Applied Biosystems) with the assistance of the Uni-
versity of Michigan DNA Sequencing Core. The primer sequen-
ces were as follows: CASP1, forward 50-GGACTCTCAGCAG-
CTCCTCAGGCA-30, reverse 50-GCAAAGCTTGACATTCCC-
TTCTGAGCC-30; IRF1, forward 50-CTGTGCGAGTGTA-
CCGGATG-30, reverse 50-ATCCCCACATGACTTCCTCTT-30;
NLRP1, forward 50-GAGTTGGGAAAACAACCTTGGT-30,
reverse 50-ACTTAAACCTCTGCTGGTAGAGA-30; NLRP3,
forward 50-GATCTTCGCTGCGATCAACAG-30, reverse 50-
CGTGCATTATCTGAACCCCAC-30; AIM2, forward 50-TG-
GGCATGCTCTCCTGAGTCCT-30, reverse 50-TCAGCCTC-
CTGATCCCTGGGGC-30; PRKR, forward 50-CTTCCATC-
TGACTCAGGTTT-30, reverse 50-TGCTTCTGACGGTATGT-
ATTA-30; MX1, forward, 50-TACCAGGACTACGAGATTG-30,
reverse 50-TGCCAGGAAGGTCTATTAG-30; ASC, forward 50-
CCTACGGCGCCGAGCTCAC-30, reverse 50-CTCCAGAGC-
CCTGGTGCGT-30; IFI44, forward 50-GGTGGGCACTAATA-
CAACTGG-30, reverse 50-CACACAGAATAAACGGCAGG-
TA-30; IL1b, forward 50-ATGTCTGGAACTTTGGCCATC-
TT-30, reverse 50-AGACAATTACAAAAGGCGAAGAAGA-
CT-30; IL18, forward 50-CCCTTTGCTCCCCTGGCGAC-30,
reverse 50-AGACTGCAGCAGGTGGCAGC-30; IL6, forward
50-ACTCACCTCTTCAGAACGAATTG-30, reverse 50-CCA-
TCTTTGGAAGGTTCAGGTTG-30; TNF, forward 50-TCCTT-
CAGACACCCTCAACC-30, reverse 50-AGGCCCCAGTTTG-
AATTCTT-30; b-actin, forward 50-CATCACGATGCCAGTG-
GTACG-30, reverse 50-AACCGCGAGAAGATGACCCAG-30.
Gene expression was normalized to that of b-actin,
relative gene expression to normal controls was calculated by the
comparative threshold cycle (Ct) method, and fold change was
expressed as 2–DDCt (25). IFN scores were calculated as previ-
ously described (26,27) for IFI44, MXA, and PRKR. Briefly, the
mean fold change in samples from healthy control subjects was
calculated, and the SLE IFN gene score was calculated as (SLE
[gene] fold change – control [mean] fold change)/SD control.
The 3 gene scores were then summed to provide a total SLE
IFN gene score. Control scores were calculated similarly.
Small interfering RNA (siRNA) and transfection.
Small interferingRNA targeting human IRF-1 orAllStarsNegative
Control siRNA (scramble) was purchased from Qiagen. The
siRNA target sequence for IRF-1 is CTGGCTAGAGATG-
CAGATTAA. Electroporation of human IRF-1 siRNA or scram-
ble siRNA into monocytes was performed with a 4D-Nucleofector
System (Lonza) using a P3 Primary Cell 4D-Nucleofector X Kit S
(Lonza). Briefly, 1 3 106 monocytes were resuspended in 20 ml of
P3 Primary Cell 4D-Nucleofector X Solution containing 250 nM
human IRF-1 siRNA or scramble siRNA, transferred into
Nucleocuvette Vessels, and electroporation was performed using a
standard program optimized for human monocytes. Immediately
after electroporation, 0.53 106 cells from each sample were diluted
into 500 ml RPMI 1640 with 5% FBS, plated onto a 48-well plate,
and cultured overnight. The cells were then treated with IFNa,
LPS, andATP, as described above.
RNA isolation and microarray procedures. Forma-
lin-fixed paraffin-embedded blocks of skin biopsy specimens
were obtained, and 5 sections (10 mm) were cut with a micro-
tome. RNA was extracted using an E.N.Z.A. FFPE RNA Kit
(Omega Bio-Tek) according to the instructions of the manu-
facturer. Complementary DNA was prepared, according to
the NuGEN Ovation PicoSL WTA System V2 Manual, P/N
M01226 v4, from ;30 ng total RNA. Biotinylated cDNA (2.5
mg) was prepared using a NuGEN Encore Biotin Module
(Encore Biotin Module Manual, P/N M01111 v6). A Poly-A
RNA Control Kit was used according to the routine procedure
at the University of Michigan Micro Array Core Lab. Labeled
cDNA was hybridized at 488C to Affymetrix Human Gene ST
2.1 array plates, which were then washed, stained, and scanned
using an Affymetrix GeneTitan system (software version
3.2.4.1515) with the assistance of personnel at the University
of Michigan DNA Sequencing Core. Quality control and
Robust Multi-array Average (28) normalization of CEL files
were performed in R version 3.1.3, using custom CDF version
19 and modified Affymetrix_1.44.1 packages from BrainArray
(http://brainarray.mbni.med.umich.edu/brainarray/default.asp).
Log2-transformed expression values were batch-corrected using
ComBat implemented in GenePattern (http://www.
broadinstitute.org/cancer/software/genepattern/). Baseline
expression was defined as minimum plus 1SD of the median
of all genes. A variance filter with a cutoff value of 80% was
then applied. Of the 25,582 unique genes represented on the
Human ST2.1 chip, a total of 20,410 genes passed the defined
criteria. The normalized data file was uploaded to the Gene
Expression Omnibus web site (http://www.ncbi.nlm.nih.gov/geo/)
under accession no. GSE81071.
Statistical analysis. Data are presented as the
mean6SEM. Student’s unpaired 2-tailed t-test was used for
analysis of differences between simultaneously cultured
1842 LIU ET AL
Figure 1. Inflammasome expression is increased in the monocytes of patients with systemic lupus erythematosus (SLE) and correlates with type
I interferon (IFN) gene expression. Total RNA was collected from the freshly isolated monocytes of SLE patients (n5 14) and control subjects
(n5 14). A, Levels of mRNA for type I IFN, inflammasome, and inflammatory cytokine genes, as measured by real-time quantitative polymerase
chain reaction, are expressed as the threshold cycle (DCt) value versus b-actin. Each symbol represents an individual sample. Horizontal lines
with error bars show the mean6 SEM of triplicate determinations for each tested gene. B, Fold change (FC) in expression of the indicated
genes versus the IFN score in each patient. *5P, 0.05; **5P, 0.01; ****5P, 0.0001.
Figure 2. Monocytes from patients with SLE demonstrate increased inflammasome activation that is enhanced by pre-exposure to type I IFNs. A,
Release of interleukin-1b (IL-1b) by control monocytes and SLE patient monocytes under different treatment conditions. Monocytes from 5 SLE patients
and 5 control subjects were treated with or without IFNa either 1 night before (O/N) or simultaneously (ST) with lipopolysaccharide (LPS) treatment.
ATP (5 mM) was added 2 hours before harvesting to activate the NLRP3 inflammasome and release mature IL-1b. Supernatants were collected, and IL-
1b production was measured by enzyme-linked immunosorbent assay. Shaded bars represent comparisons between control monocytes and SLE patient
monocytes; differences were determined by Student’s unpaired t-test. Solid bars represent comparisons between control monocytes and SLE patient mono-
cytes treated with or without IFN; differences were determined by Student’s paired t-test. Each symbol represents a single sample. Horizontal lines with
error bars show the mean6SEM. *5P, 0.05; **5P, 0.01. B, Representative Western blot for caspase 1 (Casp-1) expression in cell lysate and super-
natant (extracellular media) from the samples in A. C, Correlation between SLE Disease Activity Index (SLEDAI) scores and IL-1b production, as deter-
mined by linear regression analysis, in SLE patient monocytes treated in duplicate with or without IFNa overnight prior to inflammasome activation. See
Figure 1 for other definitions.
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Figure 3. Type I IFN enhances caspase 1 (Casp-1; 45 pro form)
expression. A, Representative Western blot for expression of anti-
bodies in lipopolysaccharide (LPS)– and/or IFNa-treated monocytes.
Cell lysates were collected, separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, and blotted against the indicated
antibodies. B, Protein band density of caspase 1, IFN regulatory
factor 1 (IRF-1), STAT-1, pSTAT-1, STAT-2, and pSTAT-2, as
digitally quantified by ImageJ. Values are the mean6SEM fold
change versus vehicle (veh)–treated control monocytes normalized to
b-actin or STAT-1/STAT-2, as indicated (n5 5 control samples and 5
SLE patient samples). *5P, 0.05; **5P, 0.01; ***5P, 0.001, by
Student’s paired t-test. See Figure 1 for other definitions.
monocytes from the control and SLE groups. For studies exam-
ining the effects on samples with multiple treatment conditions,
Student’s paired 2-tailed t-test was used to analyze differences
between the untreated and treated groups. Linear regression
analysis was used for comparison of the monocyte IFN score
with inflammasome and inflammatory genes and for compari-
son of IRF1 with CASP1 from microarray data. Both data sets
were normally distributed. P values less than 0.05 were consid-
ered significant.
RESULTS
Increased inflammasome gene expression and
IFN signature in monocytes from SLE patients. In
order to develop an understanding of the relationship
between the inflammasome and type I IFN exposure, we
first examined inflammasome- and IFN-regulated gene
expression in monocytes from SLE patients and those
from normal control subjects. Real-time qPCR on
freshly isolated monocytes demonstrated that levels of
messenger RNA (mRNA) for inflammasome genes such
as NLRP3, AIM2, and CASP1 were elevated in mono-
cytes from lupus patients compared with those from
healthy control subjects (Figure 1A). Levels of mRNA
for genes downstream of type I IFN signaling (IRF1,
PRKR, IFI44, and MX1) as well as the proinflammatory
cytokines IL6 and TNF were also significantly higher in
monocytes from SLE patients (Figure 1A).
Linear regression analysis was performed to evalu-
ate expression of IFN-regulated genes, expressed as an
IFN score (18), compared with inflammasome genes. A
strong positive correlation of CASP1 and NLRP3 with the
IFN score in SLE patients, but not in control subjects, was
noted (Figure 1B). In contrast to inflammasome genes,
the proinflammatory gene TNFA was not significantly cor-
related with the IFN-regulated genes in monocytes from
SLE patients. This suggests that the IFN–inflammasome
correlation is not a generalized inflammatory effect. These
data suggest the hypothesis that long-term exposure to
type I IFNs may result in up-regulation of inflammasome
components and facilitate inflammasome activation.
Prolonged, but not short-term, exposure to
IFNa enhances inflammasome activity in monocytes
from SLE patients and control subjects. To determine
whether IFNa promotes inflammasome activation in
monocytes, monocytes from SLE patients and controls
were primed with LPS in the presence or absence of
simultaneous addition of IFNa followed by activation
of the NLRP3 inflammasome with ATP (29,30). We
observed that at baseline, monocytes from SLE patients
had significantly enhanced IL-1b production when com-
pared with control monocytes (Figure 2A). Consistent
with previous macrophage studies (20), inhibition of IL-
1b release was detected when cells were treated simulta-
neously with IFNa (Figure 2A). However, because it is
known that SLE patients are exposed to extended IFNa
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signaling, we examined whether there were differential
effects of long-term IFNa exposure on inflammasome
activation. Thus, monocytes from SLE patients and con-
trol subjects were treated with or without IFNa over-
night prior to LPS priming and inflammasome
activation with ATP treatment.
As shown in Figure 2A, release of IL-1b was sig-
nificantly enhanced by overnight exposure to IFNa in
control monocytes and to a greater extent in the mono-
cytes of SLE patients. This effect was seen at IFNa
doses as low as 100 IU, which is estimated to be equiva-
lent to IFN concentrations in SLE plasma (31). Interest-
ingly, IL-1b production correlated with the SLE Disease
Activity Index score (32) following long-term IFN expo-
sure but not at baseline (Figure 2C). These results sug-
gested that prolonged exposure to type I IFNs, prior to
inflammasome priming with LPS, promotes inflamma-
some activity, and that patients with more active disease
may be more susceptible to the effect of type I IFNs.
In order to examine the effects of prolonged type
I IFN exposure on expression of IFN-regulated and
inflammasome proteins, Western blot analysis of control
monocytes and monocytes from SLE patients was per-
formed. Evidence of long-term type I IFN activation of
monocytes from SLE patients at baseline was observed
as reflected by increased pSTAT-1 and IRF-1 expres-
sion (Figure 3A). Importantly, expression of the p45 pro
form of caspase 1 was also increased in monocytes from
SLE patients compared with control monocytes at base-
line (Figure 3B). Overnight exposure to IFNa alone sig-
nificantly up-regulated phosphorylation of STAT-1 and
STAT-2 and up-regulated IRF-1 and caspase 1 expres-
sion in control monocytes. IFNa induced moderate, but
not significant, increases in caspase 1 expression over base-
line levels in monocytes from SLE patients. The addition of
LPS after overnight exposure to IFNa resulted in even
greater expression of caspase 1 and IRF-1 in monocytes
from SLE patients and control subjects (Figure 3B), imply-
ing a synergistic effect of Toll-like receptor (TLR) and IFN
signaling in caspase 1 expression. Taken together, these data
suggested that exposure to type I IFNs prior to priming and
activation of the inflammasome results in enhanced caspase
1 expression and increased inflammasome activity, whereas
if TLR-4 and IFN signals are received simultaneously,
inflammasome activity is inhibited.
Knockdown of IRF-1 effectively attenuates
IFNa-mediated caspase 1 expression and inflamma-
some hyperactivation in monocytes from SLE patients.
IRF-1 is a transcription factor that is activated by type I
IFN signaling and is important for the development (33)
Figure 4. Inhibition of interferon (IFN) regulatory factor 1 expression prevents IFNa-induced up-regulation of caspase 1. A, Western blot for
caspase 1 and IRF-1 expression in control monocytes transfected with human IRF-1 small interfering RNA (siRNA) or scramble (SCR) by elec-
troporation and then treated with vehicle or IFNa for 6 hours. B, Densitometric analysis of the caspase 1 and IRF-1 protein expression shown
in A. C, Western blot for caspase 1 and IRF-1 expression in control monocytes incubated with 50 mM 4,5,6,7-tetrabromobenzotriazole (TBB), an
inhibitor of IRF-1 regulator casein kinase II, prior to 6-hour stimulation with IFNa. D, Densitometric analysis of the caspase 1 and IRF-1
expression shown in C. Values are the mean6 SEM fold change versus vehicle-treated control (n5 6 experiments in A and B; n5 4 experiments
in C and D). *5P, 0.05; **5P, 0.01. See Figure 3 for other definitions.
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and prediction (34) of a treatment response in lupus
nephritis (34). Importantly, IRF-1 has been identified as a
central regulator of target genes in monocytes from lupus
patients (35) and has been reported as a transcription fac-
tor of caspase 1 (36,37). Our data support parallel regula-
tion of IRF-1 and caspase 1 downstream of IFNa. To
determine whether an IFNa-mediated increase in caspase
1 expression required IRF-1, we knocked down the
expression of IRF-1 by targeting human IRF-1 in control
monocytes with siRNA followed by treatment with or
without IFNa. As shown in Figures 4A and B, we were
able to achieve a 50% reduction in IRF-1 expression when
this method was used. Importantly, knockdown of IRF-1
significantly inhibited basal and IFNa-induced expression
of caspase 1 (Figures 4A and B). Inhibition of IRF-1 tran-
scriptional activity with TBB, an inhibitor of casein kinase
II, an upstream positive regulator of IRF-1 (38), also gave
similar results (Figures 4C and D).
In order to determine whether inhibition of IRF-
1 was sufficient to normalize caspase 1 overexpression
and inflammasome hyperactivation in the monocytes of
SLE patients, which have prolonged exposure to type I
IFNs, monocytes from SLE patients and control mono-
cytes were then transfected with scramble or human
IRF-1 siRNA followed by priming of the inflammasome
with LPS and activation with ATP. A reduction in IRF-
1 expression significantly down-regulated baseline and
LPS-induced caspase 1 expression in monocytes from
patients with SLE and control monocytes (Figures 5A
and B). Importantly, IRF-1 inhibition normalized IL-1b
activation and secretion following LPS priming and
ATP-mediated inflammasome activation in monocytes
from SLE patients to levels similar to those in
control monocytes and had further inhibitory effects
on IL-1b production in control cells (Figure 5C). Inhibi-
tion of IRF-1 with TBB also inhibited IFNa-mediated
Figure 5. Interferon (IFN) regulatory factor 1 regulates caspase 1 (p45 pro form) expression and interleukin-1b (IL-1b) production in the monocytes
of patients with systemic lupus erythematosus (SLE). A, Western blot for expression of the indicated proteins in cell lysates. Monocytes from lupus
patients and control (CNTL) subjects were transfected with human IRF-1 small interfering RNA (siRNA) or scramble (SCR) and treated with vehicle
or LPS for 4 hours. B, Densitometric measurement of data shown in A. Values are the fold change versus b-actin (n5 3). Each symbol represents an
individual sample. Horizontal lines with error bars show the mean6 SEM. C, IL-1b production in monocytes treated as described in A, as measured
by enzyme-linked immunosorbent assay (ELISA). Treatment was followed by stimulation of the inflammasome with 5 mM ATP. Each symbol repre-
sents the average of duplicate experiments in 5 SLE patients and 5 control subjects. Horizontal lines with error bars show the mean6 SEM. D, IL-1b
production in monocytes, as measured by ELISA. Monocytes were stimulated overnight with IFNa or 50% control or SLE patient serum in the pres-
ence or absence of DMSO (vehicle) or 50 mM 4,5,6,7-tetrabromobenzotriazole (TBB) followed by LPS priming and inflammasome activation with
5 mM ATP. Each symbol represents the average of duplicate experiments in 7 control serum samples and 7 SLE patient samples. Horizontal lines
with error bars show the mean6SEM. E, Linear regression analysis showing the correlation between CASP1 and IRF1 log2-transformed mRNA
expression values (determined using microarray data) in biopsy specimens obtained from the lesional skin of patients with discoid lupus erythematosus
(DLE) and patients with subacute cutaneous lupus erythematosus (SCLE) (left), and from control skin (right). *5P, 0.05; **5P, 0.01;
****5P, 0.0001 by Student’s paired t-test. NS5not significant (see Figure 3 for other definitions).
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enhancement of IL-1b release after inflammasome acti-
vation (Figure 5D). These data suggest that type I IFN–
mediated enhanced IRF-1 activity in monocytes from
patients with SLE is driving amplified inflammasome
activity.
To investigate whether IFN activity in the serum
of SLE patients can enhance inflammasome activation
in control monocytes, we incubated control monocytes
with IFNa or serum from controls or SLE patients over-
night prior to inflammasome activation with LPS and
ATP. We detected a robust increase in IL-1b release
from monocytes that were preincubated overnight with
control serum prior to inflammasome stimulation, and
this effect was amplified with the use of serum from
SLE patients (Figure 5D). Importantly, we were able to
significantly diminish the enhanced effect of serum from
SLE patients on inflammasome activation via IRF-1
inhibition with TBB, returning IL-1b release to levels
obtained with control serum. Taken together, these data
suggest that IFNs present in the serum of lupus patients
can enhance inflammasome activation in an IRF-1–
dependent manner.
Cutaneous lupus lesions are marked by strong
type I IFN signatures (39,40) and monocyte infiltra-
tion (41,42). In order to confirm the relevance of
caspase 1 and IRF-1 dysregulation in an SLE disease
phenotype, expression of both genes was assessed in
lesional skin biopsy specimens obtained from 47
patients with DLE and 43 patients with SCLE and
biopsy specimens obtained from 13 normal control
subjects. As shown in Figure 5E, there was a strongly
significant correlation between IRF1 and CASP1
expression in both DLE and SCLE. This correlation
was also observed when each disease subtype was
considered separately: for CASP1 versus IRF1 in
DLE, R25 0.3315 and P# 0.0001; for CASP1 versus
IRF1 in SCLE, R25 0.2129 and P5 0.002. No corre-
lation between IRF1 and CASP1 expression was
noted in control skin. Taken together, these data
suggest that chronic type I IFN exposure drives
enhanced inflammasome activity in SLE in an IRF-
1–dependent manner.
DISCUSSION
Data from recent studies have supported the
role of the inflammasome in contributing to the patho-
genesis of SLE (1,4–7,9,10,43). In the current study,
we provide mechanistic data on the intersection of
inflammasome activation with another SLE-relevant
innate immune pathway, long-term type I IFN exposure.
Indeed, we demonstrate that prolonged exposure to
IFNa promotes inflammasome activation in the mono-
cytes of SLE patients in an IRF-1–dependent manner.
The mechanisms by which the inflammasome
impacts SLE pathogenesis are being defined. Up-
regulation of inflammasome gene expression and
inflammasome activity has been identified in both
human and murine lupus (1,2,4,6,7,44). Inhibition of
caspase 1– or NLRP3-mediated inflammasome signal-
ing in murine models demonstrated that inflamma-
some pathways contribute to disease pathogenesis via
promotion of autoantibody production, endothelial
dysfunction, and nephritis (5,9,10,12). Activation of
the inflammasome occurs downstream of SLE-specific
factors, including autoantibodies and dysregulated
neutrophil extracellular traps (1,2,6,7), which may
implicate the inflammasome as a regulatory switch
between autoimmunity and inflammation-mediated
organ damage.
Links between type I IFN and the inflammasome
in SLE have been less studied. Bisphenol A, a chemical
that up-regulates both type I IFN production and
inflammasome activity in monocytes (21), may be linked
with autoimmunity, but the question of whether the 2
pathways intersected was not examined. A study by
Yang et al examining human PBMC populations dem-
onstrated decreased expression of NLRP3 in samples
from SLE patients versus control samples (19). How-
ever, our study, which utilized purified monocyte
populations, clearly shows increased expression of
NLRP3 and NLRP3-mediated inflammasome activity in
monocytes from SLE patients compared with control
monocytes. It is possible that analysis of a mixed cell
population diluted the expression changes in monocytes
from SLE patients in the study by Yang and colleagues.
Another study suggested that IFNb is repressive to
inflammasome activation through production of IL-10
in bone marrow–derived murine macrophages (20).
Consistent with that study, we demonstrated that short-
term exposure to IFNa represses inflammasome activa-
tion, but that prolonged exposure, as seen in SLE, pro-
motes inflammasome activation. This concept is
supported by the strong correlation between NLRP3
and type I IFN–regulated genes in monocytes from
patients with SLE but not in control monocytes and in
cutaneous lupus lesions.
Surprisingly, we did not observe a correlation
between AIM2, an inflammasome scaffold that is acti-
vated by double-stranded DNA and known to be up-
regulated by type I IFNs (45), and monocyte IFN scores.
This may reflect increased levels of circulating BAFF in
SLE patients, which is known to repress absent in mela-
noma (Aim2) expression (46). The role of Aim2 in SLE
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is multifaceted, and Aim2 may have inhibitory and pro-
moting effects on autoimmunity (for review, see ref. 47).
No correlation between another inflammasome scaffold,
NLRP1, and IFN scores was noted. NLRP1 has genetic
links to SLE (48), and transient type I IFN exposure has
been reported to down-regulate NLRP1 inflammasomes
(20); however, the role of NLRP1 in SLE remains
undefined.
Our data show that inhibition of IRF-1 in the
monocytes of SLE patients normalizes inflammasome
hyperactivity. IRF-1 is increasingly becoming a target of
investigation in SLE pathogenesis. Deletion of IRF-1 is
protective in the MRL/lprmodel of lupus (49). Expression
of IRF-1–regulated genes is increased in SLE by an aver-
age of 7.8%, secondary to increased IRF-1 binding to
H3K4me3 sites (35). Furthermore, increased IRF-1
expression is observed in biopsy specimens from patients
with lupus nephritis (33), DLE, and SCLE and in mono-
cytes from patients with SLE (35). Increased expression
of IRF-1 facilitates type I IFN–accelerated lupus nephritis
in (NZB/NZW)F1 mice, and its down-regulation corre-
lates with a reduction in lupus nephritis activity (33).
Importantly, IRF-1 expression in the kidney may also be
predictive of a treatment response in lupus nephritis (34).
The addition of serum to monocytes has been
shown to facilitate inflammasome activation in part via
immune complexes and stimulation of Fcg receptors in
the context of TLR signaling (1,6,7,50). We detected
similar enhancement of inflammasome activation when
control monocytes were exposed to serum from SLE
patients and control serum, although the effect was
greater in serum from SLE patients.
Interestingly, the enhanced effects of SLE patient
serum on IL-1b release returned to the level in control
serum following inhibition of IRF-1 via TBB. This sug-
gests that increased IFN activity in the serum of SLE
patients is a significant contributor to inflammasome acti-
vation in an IRF-1–dependent manner. The residual
enhancement of inflammasome activity in the presence of
TBB is likely secondary to immunoglobulin effects.
Interest in the inflammasome as a promoter of
SLE organ damage is growing. Our work supports a role
for long-term type I IFN exposure as a mechanism by
which the inflammasome is hyperactivated in SLE
patients and identifies IRF-1 as an important regulator
of this process. These data will inform development of
novel therapeutic targets in SLE.
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